Delta-fly pharma inc.: abstracts submission for phase i clinical trial of dfp-14927 to 2024 asco annual meeting

Tokushima, japan--(business wire)--following the previous information on jan. 5th. in 2024, we are excited to share our latest development status. a phase i clinical dose-finding study of dfp-14927 in patients with solid tumors has been completed at md anderson cancer center and the university of california, los angeles in the united states. subsequently, the concentration of dfp-10917, the active component of dfp-14927, delivering into cancer tissue in patients treated with dfp-14927 is being.
DAL Ratings Summary
DAL Quant Ranking